Widower warns of 'sneaky' symptoms of ovarian cancer
A widower has said his wife received a late and terminal diagnosis due to an ongoing lack of awareness about symptoms of ovarian cancer among health professionals.
Stephen McCormick, whose wife Julie was diagnosed with stage 3 ovarian cancer, said the disease shouldn't be ruled out as symptoms can be associated with other less serious conditions.
About 200 women are diagnosed with ovarian cancer in Northern Ireland each year.
The Department of Health and the Public Health Agency both said that due to constraints on the health budget there has been a "freeze" on almost all advertising spend across Health and Social Care.
"I think doctors need to rule it in before they rule it out, particularly if symptoms persist when a woman is being investigated for gynaecological or stomach problems," the County Down man said.
Julie first complained of pelvic pain in 2021, however, it took a further two and a half years of investigations and tests before ovarian cancer was diagnosed.
Julie died 12 months later, aged 65.
Mr McCormick said his wife, an oncology nurse, was "fooled" by early tests being negative despite prolonged symptoms telling her something wasn't right.
A CA125 blood test, which is used to measure a level of protein in the blood and is not a definitive test for ovarian cancer was initially clear and caused no concern.
But according to Mr McCormick, despite his wife's constant visits to the GP and other specialists with stomach pain and gynae issues, ovarian cancer wasn't a line of inquiry.
Mr McCormick said he's "passionate" about raising awareness of ovarian cancer and is "on a mission" to get a public awareness campaign up and running across Northern Ireland.
That mission began on 23 June 2024, the day Julie died.
Posting on social media that day, Mr McCormick urged the public to be aware of the "sneaky symptoms" of ovarian cancer and to get checked if they persist.
One year on, he said little has changed with no desire among politicians and health officials to put it on the Executive's agenda.
"I'd like a big billboard, radio and television campaign educating people about the symptoms and that if they persist you should continue seeking help and suggesting being tested for ovarian cancer," said Mr McCormick.
"When you are diagnosed late, the outcomes are much poorer and therefore if women can get to see their GP sooner, they have a better chance of being diagnosed and a better chance of survival."
He also said he isn't confident that the Department of Health will decide to go big on the cancer as he appreciates it has a long list of priorities.
Research by Queen's University Belfast has found the most common route for women to be diagnosed with ovarian cancer was in an Emergency Department.
Between 2017 and 2021, 35% (70) of cases were diagnosed on average each year via an emergency presentation, and 27% (55) of cases were diagnosed by a red-flag referral route.
Dr Damien Bennett, director of the NI Cancer Registry, said the findings highlighted the need to drive home the message that if symptoms persist - including if they happen 12 times in a month - it is not something that should be ignored and should be immediately followed up with the woman's GP.
"These symptoms can overlap with other conditions that are benign and can potentially make it more difficult for the public to potentially approach health care professionals," he said.
"Those symptoms also make it more difficult for health care professionals to come to a diagnosis - but the greater awareness about all of this the better."
The research also found that 32% of cases were diagnosed at stage 1 (early stage), while 20% were diagnosed at an advanced stage.
On average there were 122 deaths per year from ovarian cancer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Psychiatrists Report Moral Injury Amid Mental Health Crisis
Delayed access to psychiatric treatment is causing 'moral injury' to UK psychiatrists and harming their patients, the Royal College of Psychiatrists (RCPsych) has warned. College President Dr Lade Smith told delegates at its International Congress 2025 that psychiatrists face 'growing emotional and ethical distress' as they navigate a mental health system 'stretched beyond its limits'. The survey, which ran from 3 February to 2 March this year, received responses from 1012 psychiatrists in England, representing 6.3% of working members in the RCPsych database. Four in 5 (81%) respondents said they had directly experienced or witnessed moral injury during decisions about patient admission or discharge. The college defined moral injury as a strong cognitive and emotional response following events that violate one's moral or ethical code. Almost three quarters of respondents (73%) admitted making admission or discharge decisions 'based on factors other than the patient's clinical need and best interests'. Almost half (47%) reported daily delays in timely admissions or provision of inpatient mental health treatment due to capacity shortages. Almost as many (44%) said they regularly heard about patients waiting for treatment in emergency departments or places of safety. Worsening Mental Health Crisis NHS data indicate that one in four adults experience at least one diagnosable mental health problem each year. Mental health issues are the largest single cause of disability in the UK. A January report from the Health Foundation highlighted a recent sharp rise in mental health-related economic inactivity. The number of workers aged 16-34 limited in work by mental health has more than quadrupled in the last decade. The mental health charity Mind estimates that poor mental health costs £300 billion a year in England alone. Chronic Underfunding and Resource Shortages RCPsych criticised the longstanding underfunding of mental health services. Although mental illness accounts for more than 20% of England's disease burden, it will receive less than 9% of health funding this year. Smith told the conference in Newport, Wales, that the consequence of systemic issues, long-term underinvestment, and a failure to follow an evidence-based approach to care, have resulted in 'an erosion of standards in the mental health system'. The college reported that patients are becoming increasingly unwell or in crisis 'due to an inability to access timely psychiatric treatment'. They also face disrupted continuity of care that creates difficulties maintaining therapeutic relationships. Local capacity pressures may affect professional decisions and put patients at risk, Lade said. Consequently, practitioners are left feeling that their treatments standards fall below what they consider to be acceptable. This leads to feelings of guilt, shame, burnout, frustration, and isolation, according to the RCPsych. Increased Use of Unsuitable Out-of-Area Placements One in three psychiatrists who responded to the survey reported weekly admissions to inappropriate wards. Patients are often placed far from home where they are separated from their families. This leads to longer stays and higher NHS costs, despite government pledges to end this by 2021. The RCPsych's mental health watch dashboard shows that inappropriate out-of-area placements rose 22% from 32,617 between February-April 2024 to 39,779 in the same period this year. Survey respondents linked lack of community mental health investment and supported housing with increased crises, delayed discharges, impaired recovery, and more readmissions. Financial Pressures Override Clinical Judgement The college said that the survey findings painted 'a distressing picture of psychiatrists carrying the weight of trying to deliver the best possible care to people with mental illness, with limited means to do so'. 'Provisions are now so threadbare that psychiatrists are having to make life and death decisions based on financial rather than clinical concerns,' Smith said.
Yahoo
2 hours ago
- Yahoo
How your gut bacteria could help detect pancreatic cancer early
Whether you had breakfast this morning or not, your pancreas is working quietly behind the scenes. This vital organ produces the enzymes that help digest your food and the hormones that regulate your metabolism. But when something goes wrong with your pancreas, the consequences can be devastating. Pancreatic cancer has earned the grim nickname 'the silent killer' for good reason. By the time most patients experience symptoms, the disease has often progressed to an advanced stage where treatment options become severely limited. In the UK alone, over 10,700 new cases and 9,500 deaths from pancreatic cancer were recorded between 2017 and 2019, with incidence rates continuing to rise. The most common form, pancreatic ductal adenocarcinoma (PDAC), develops in the pancreatic duct – a tube connecting the pancreas to the small intestine. When tumours form here, they can block the flow of digestive enzymes, causing energy metabolism problems that leave patients feeling chronically tired and unwell. Yet these symptoms are often so subtle that they're easily dismissed or attributed to other causes. Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences. Now researchers are turning to an unexpected source for early PDAC detection: faecal samples. While analysing poo might seem an unlikely approach to cancer diagnosis, scientists are discovering that our waste contains a treasure trove of information about our health. This is because your gut is home to trillions of bacteria – in fact, bacterial cells in your body outnumber human cells by roughly 40 trillion to 30 trillion. These microscopic residents form complex communities that can reflect the state of your health, including the presence of disease. Since PDAC typically develops in the part of the pancreas that connects to the gut, and most people have regular bowel movements, stool samples provide a practical, non-invasive window into what is happening inside the body. This innovative approach has been validated in studies across several countries, including Japan, China and Spain. The latest breakthrough comes from a 2025 international study involving researchers in Finland and Iran, which set out to examine the relationship between gut bacteria and pancreatic cancer onset across different populations. The researchers collected stool samples and analysed bacterial DNA using a technique called 16S rRNA gene amplicon sequencing. Despite the complex name, the principle is straightforward: scientists sequence and compare a genetic region found in every bacterium's genome, allowing them to both identify and count different bacterial species simultaneously. The findings from the Finnish-Iranian study were striking. Patients with PDAC exhibited reduced bacterial diversity in their gut, with certain species either enriched or depleted compared with healthy people. More importantly, the team developed an artificial intelligence model that could accurately distinguish between cancer patients and healthy people based solely on their gut bacterial profiles. The field of microbiome research is evolving rapidly. While this study used amplicon sequencing, newer methods like 'shotgun metagenomic sequencing' are providing even more detailed insights. This advanced technique captures the entire bacterial genome content rather than focusing on a single gene, offering an unprecedented resolution that can even detect whether bacteria have recently transferred between individuals. These technological advances are driving a fundamental shift in how we think about health and disease. We're moving from a purely human-centred view to understanding ourselves as 'human plus microbiome' – complex ecosystems where our bacterial partners play crucial roles in our wellbeing. The possibilities go well beyond pancreatic cancer. At Quadram, we're applying similar methods to study colorectal cancer. We've already analysed over a thousand stool samples using advanced computational tools that piece together bacterial genomes and their functions from fragmented DNA. This ongoing work aims to reveal how gut microbes behave in colorectal cancer, much like other scientists have done for PDAC. The bidirectional interactions between cancer and bacteria are particularly fascinating – not only can certain bacterial profiles indicate disease presence, but the disease itself can alter the gut microbiome, as we previously showed in Parkinson's disease, creating a complex web of cause and effect that researchers are still unravelling. Nonetheless, by understanding how our microbial partners respond to and influence disease, we're gaining insights that could revolutionise both diagnosis and treatment. Our past research has shown this to be incredibly complex and sometimes difficult to understand, but developments in biotechnology and artificial intelligence are increasingly helping us to make sense of this microscopic world. For cancer patients and their families, this and other advancements in microbiome research offer hope for earlier detection. While we're still in the early stages of translating these findings into clinical practice, the potential to catch this silent killer before it becomes deadly could transform outcomes for thousands of patients, but will require more careful and fundamental research. The microbial perspective on health is no longer a distant scientific curiosity – it's rapidly becoming a practical reality that could save lives. As researchers continue to explore this inner frontier, we're learning that the answer to some of our most challenging medical questions might be hiding in plain sight – in the waste we flush away each day. This article is republished from The Conversation under a Creative Commons license. Read the original article. Falk Hildebrand receives funding from the UKRI, BBSRC, NERC and ERC. Daisuke Suzuki receives funding from Japan Society for the Promotion of Science.
Medscape
2 hours ago
- Medscape
Epilepsy Medications Drive Adverse Pregnancy Outcomes
TOPLINE: Maternal epilepsy was associated with increased odds of adverse perinatal outcomes, but most associations were driven by prenatal exposure to antiseizure medications (ASMs) rather than epilepsy itself. METHODOLOGY: Researchers conducted a retrospective population-based cohort study using national health data from Scotland between 2009 and 2021. This study included 629,200 pregnancies (2022 in women with epilepsy and 627,178 in women without epilepsy). International Classification of Diseases, Tenth Revision codes were used to identify maternal epilepsy from pregnancy records or hospital admissions within 2 years prior to the estimated conception through pregnancy. The analysis included exposure to ASMs, defined as any ASM dispensed between 30 days before the estimated conception and the end of pregnancy, with 4406 pregnancies exposed to ASMs and 624,794 unexposed. The primary outcome was the association between maternal epilepsy and adverse perinatal outcomes; secondary outcomes included effect estimates for exposure to specific ASM monotherapies (valproate, carbamazepine, lamotrigine, levetiracetam, or topiramate) vs no exposure. TAKEAWAY: Compared with women without epilepsy, those with epilepsy showed increased odds of induced labour (adjusted odds ratio [aOR], 1.17; 95% CI, 1.02-1.34), after adjusting for prenatal exposure to ASMs. Prenatal exposure to ASMs was associated with increased odds of preterm birth (aOR, 1.47; 95% CI, 1.25-1.74), induced labour (aOR, 1.38; 95% CI, 1.25-1.52), and NICU admission (aOR, 1.54; 95% CI, 1.33-1.78). Valproate monotherapy showed the strongest association with congenital conditions (aOR, 3.91; 95% CI, 2.36-6.49), followed by carbamazepine monotherapy (aOR, 1.90; 95% CI, 1.16-3.10). IN PRACTICE: "Maternal epilepsy is associated with many adverse perinatal outcomes, but most are driven by prenatal ASM exposure. We postulate that joint comprehensive care between obstetricians and epileptologists or other specialists who prescribe ASMs could improve perinatal outcomes," the authors of the study wrote. SOURCE: This study was led by Paolo Pieirino Mazzone, Muir Maxwell Epilepsy Centre, University of Edinburgh, Edinburgh, Scotland, and was published online on June 16, 2025, in Epilepsia. LIMITATIONS: This study was limited by its inability to account for epilepsy characteristics such as aetiology, type/syndrome, or seizure frequency/severity. This study could not determine whether individuals in the group of women with epilepsy without prenatal exposure to ASMs were misclassified because some might have had resolved epilepsy or never had epilepsy. ASM treatment duration, trimester of dispensation, and reasons for ASM use aside from epilepsy were not investigated. DISCLOSURES: This study did not receive any external funding. One author reported receiving consultant, lecture, and/or conference-attendance fees from various sources, and another author reported receiving external fund support unrelated to this study. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
